The vaccine, called mFlusiva, is the first mRNA-based flu shot to receive regulatory approval anywhere in the world

The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.

The FDA has approved the nation’s first messenger RNA-based influenza vaccine, marking a significant development in the fight against the respiratory illness — and the end of a…

The vaccine, developed by Moderna, is approved for adults ages 50 to 64 and those 65 and older, who face the highest risk of severe illness.